2型糖尿病患者使用SGLT2抑制剂与痴呆及帕金森病风险
这项基于韩国国民健康保险服务数据库的回顾性队列研究纳入1,348,362例≥40岁、2014至2019年间开始使用降糖药的2型糖尿病患者,经1:1倾向评分匹配后分析358,862例。SGLT2抑制剂使用与阿尔茨海默病(aHR 0.81)、血管性痴呆(aHR 0.69)、帕金森病(aHR 0.80)及全因痴呆(aHR 0.79)风险降低相关。
要点
- SGLT2抑制剂使用与阿尔茨海默病风险降低相关(aHR 0.81,95%CI 0.76-0.87)。
- SGLT2抑制剂使用与血管性痴呆风险降低相关(aHR 0.69,95%CI 0.60-0.78)。
- SGLT2抑制剂使用与帕金森病风险降低相关(aHR 0.80,95%CI 0.69-0.91)。
核心结论
- 在这项全国性人群研究中,SGLT2抑制剂使用显著降低2型糖尿病患者神经退行性疾病的风险,且不受合并症和生化参数等多种因素影响。
- 本研究提供II级证据表明SGLT2类降糖药降低糖尿病患者痴呆和帕金森病的风险。
研究设计与样本
- 基于韩国国民健康保险服务数据库的回顾性队列研究,纳入1,348,362例≥40岁、2014至2019年间开始使用降糖药的2型糖尿病患者。
- 经1:1倾向评分匹配(SGLT2抑制剂对比其他口服降糖药)后,分析队列为358,862例参与者。
- 采用Cox比例风险模型分析SGLT2抑制剂使用与痴呆及帕金森病风险的关联。
主要发现
- 在分析的358,862例参与者中(平均[SD]年龄57.8[9.6]岁;58.0%为男性),共发生6,837例新发痴呆或帕金森病事件。
- 设置6个月用药滞后期的分析中,SGLT2抑制剂使用与阿尔茨海默病风险降低相关(aHR 0.81,95%CI 0.76-0.87)。
- SGLT2抑制剂使用与血管性痴呆风险降低相关(aHR 0.69,95%CI 0.60-0.78)。
- SGLT2抑制剂使用与帕金森病风险降低相关(aHR 0.80,95%CI 0.69-0.91)。
- 与其他口服降糖药相比,SGLT2抑制剂使用与全因痴呆风险降低21%相关(aHR 0.79,95%CI 0.69-0.90),与全因痴呆和帕金森病复合终点风险降低22%相关(aHR 0.78,95%CI 0.73-0.83)。
关键数值与推荐
- 主要结局为阿尔茨海默病、血管性痴呆和帕金森病的个体发病率。
- 次要结局为全因痴呆(阿尔茨海默病、血管性痴呆及其他痴呆)以及全因痴呆和帕金森病的复合终点。
- SGLT2抑制剂使用与神经退行性疾病风险降低的关联不受性别、Charlson合并症指数、糖尿病并发症、合并症和用药的影响。
- 进一步校正健康筛查生化变量(包括血压、血糖、血脂谱和肾功能)的敏感性分析结果总体一致。
临床怎么用
- 原文未据此给出推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Despite the mechanistic potential of sodium-glucose cotransporter 2 inhibitor (SGLT2i) to improve neurologic outcomes, the efficacy of SGLT2i in neurodegenerative disorders among patients with type 2 diabetes is not well established. This population-based cohort study aimed to investigate the association of SGLT2i use with risks of incident dementia and Parkinson disease (PD) in patients with type 2 diabetes. METHODS: This was a retrospective examination of data from a cohort of 1,348,362 participants with type 2 diabetes (≥40 years), who started antidiabetic drugs from 2014 to 2019, evaluated using the Korean National Health Insurance Service Database. Propensity score matching (1:1; SGLT2i to other oral antidiabetic drugs [OADs]) produced a cohort of 358,862 participants. Primary outcomes were the individual incidence of Alzheimer disease (AD), vascular dementia (VaD), and PD. Secondary outcomes were all-cause dementia (AD, VaD, and other dementia) and a composite of all-cause dementia and PD. Cox proportional hazards models were used to investigate the association between SGLT2i use and the risks of dementia and PD. RESULTS: From the 358,862 participants analyzed (mean [SD] age, 57.8 [9.6] years; 58.0% male), 6,837 incident dementia or PD events occurred. Regarding the individual endpoints, SGLT2i use was associated with reduced risks of AD (adjusted hazard ratio [aHR] 0.81, 95% CI 0.76-0.87), VaD (aHR 0.69, 95% CI 0.60-0.78), and PD (aHR 0.80, 95% CI 0.69-0.91) with a 6-month drug use lag period. In addition, use of SGLT2i was associated with a 21% lower risk of all-cause dementia (aHR 0.79, 95% CI 0.69-0.90) and a 22% lower risk of all-cause dementia and PD than use of other OADs (aHR 0.78, 95% CI 0.73-0.83). The association between the use of SGLT2i and the lowered risk of these neurodegenerative disorders was not affected by sex, Charlson Comorbidity Index, diabetic complications, comorbidities, and medications. Sensitivity analysis further adjusting for bioclinical variables from health screening tests, including blood pressure, glucose, lipid profiles, and kidney function, yielded generally consistent results. DISCUSSION: In this nationwide population-based study, SGLT2i use significantly reduced the risks of neurodegenerative disorders in patients with type 2 diabetes independent of various factors including comorbidities and bioclinical parameters. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that SGLT2 antidiabetic drugs decrease the risk of dementia and PD in people with diabetes.
引用
- Kim HK, Biessels GJ, Yu MH, et al. SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. Neurology. 2024. PMID: 39292986. doi:10.1212/WNL.0000000000209805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。